Related
Yes Securities has buy call on Cadila Healthcare with a target price of Rs 425. The current market price of Cadila Healthcare Ltd. is Rs 400.75. Time period given by analyst is Intra Day when Cadila Healthcare Ltd. price can reach defined target. .
Cadila Healthcare Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 41026.48 Crore) operating in Pharmaceuticals sector.
Cadila Healthcare Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2021.
Financials
For the quarter ended 31-12-2021, the company reported a Consolidated Total Income of Rs 3715.80 Crore, down -3.19 % from last quarter Total Income of Rs 3838.10 Crore and down -2.81 % from last year same quarter Total Income of Rs 3823.10 Crore. Company reported net profit after tax of Rs 488.30 Crore in latest quarter.
Investment Rationale
The stock has turned upwards after taking support at the 61.8% Fibonacci retracement level paced at 395. Further, it has turned upwards after reaching the oversold zone and testing 200-WMA suggesting a short-covering rally could be on the cards. Further, RSI has also formed a higher low after a positive divergence confirming immediate bullishness.
Promoter/FII Holdings
Promoters held 74.88 per cent stake in the company as of 31-Dec-2021, while FIIs owned 3.79 per cent, DIIs 11.81 per cent.
Cadila Healthcare Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 41026.48 Crore) operating in Pharmaceuticals sector.
Cadila Healthcare Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2021.
Financials
For the quarter ended 31-12-2021, the company reported a Consolidated Total Income of Rs 3715.80 Crore, down -3.19 % from last quarter Total Income of Rs 3838.10 Crore and down -2.81 % from last year same quarter Total Income of Rs 3823.10 Crore. Company reported net profit after tax of Rs 488.30 Crore in latest quarter.
Investment Rationale
The stock has turned upwards after taking support at the 61.8% Fibonacci retracement level paced at 395. Further, it has turned upwards after reaching the oversold zone and testing 200-WMA suggesting a short-covering rally could be on the cards. Further, RSI has also formed a higher low after a positive divergence confirming immediate bullishness.
Promoter/FII Holdings
Promoters held 74.88 per cent stake in the company as of 31-Dec-2021, while FIIs owned 3.79 per cent, DIIs 11.81 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Pick the best companies to invest
BECOME AN ETPRIME MEMBERRead More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by